FDA panel backs expanded label for CAIV-T

MedImmune (MEDI) said on Wednesday that FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of expanding

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE